hr

Documents about hr

• HR i förändring: Emotionshantering och förändringskompetens i ett devolverat HR-arbete#185286GUPEA
• HR i ett organisatoriskt spänningsfält#970895GUPEA
• Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer#208459ClinicalTrials.gov
• hr time 3#68119W3C TR
• hr time 2#68128W3C TR
• Валидность и предвзятость в HR-отборе: баланс между объективностью и человеческим фактором#27631DataCite
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)#852502ClinicalTrials.gov
• Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing#854173ClinicalTrials.gov
• A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer#208458ClinicalTrials.gov
• Untangling human resource management and employee wellbeing relationships: Differentiating job resource HR practices from challenge demand HR practices#246220DORAS
• QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer#852754ClinicalTrials.gov
• Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer#887354ClinicalTrials.gov
• A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer#968441ClinicalTrials.gov
• Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.#136325ClinicalTrials.gov
• Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC#911541ClinicalTrials.gov
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)#864759ClinicalTrials.gov
• An Architectural Approach to Managing Knowledge Stocks and Flows: Implications for Reinventing the HR Function#214854BYU ScholarsArchive
• A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.#871893ClinicalTrials.gov
• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)#913344ClinicalTrials.gov
• NB2013-HR German (GPOH) / Dutch (DCOG) Trial#154651ClinicalTrials.gov
• STRENGTHENING EMPLOYEE COMMITMENT THROUGH FLEXIBLE WORK MODELS AND SUSTAINABLE HR PRACTICES IN INDONESIA STARTUPS#179507Zenodo (CERN)
• Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus#202219Europe PMC
• Automating HR Processes with Robotic Process Automation (RPA)#98058PhilArchive
• Age‐Inclusive HR Practices as Resource Passageways: Explaining Retirement Intentions Through Employability and Job Insecurity#454385EconStor
• Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer#806269ClinicalTrials.gov
• A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer#839876ClinicalTrials.gov
• ALGORITHMIC MANAGEMENT IN THE WORKPLACE: A DUAL-PATHWAY MODEL FOR HR GOVERNANCE, EMPLOYEE AUTONOMY, AND ETHICAL IMPLEMENTATION#179513Zenodo (CERN)
• Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor#834298ClinicalTrials.gov
• HR-EGG in Medically Refractory Gastroparesis#321641ClinicalTrials.gov
• GENERATIV AI OCH LIVSLÅNGT LÄRANDE: En kvalitativ studie om hur AI kan stödja livslångt lärande inom HR i svenska organisationer#185260GUPEA
• Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)#868305ClinicalTrials.gov
• Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,#870720ClinicalTrials.gov
• Blockchain Technology in HR Data Management#174121Zenodo (CERN)
• Neurobiology of Mathematics (Cap 10) - hr#184037Zenodo
• Insomnia and women: exploring vulnerability, impact, and intervention.#220835NCBI PubMed Central
• To Evaluate 24-hr Glucose After OD vs BD AZD1656#349925ClinicalTrials.gov
• Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis#883636ClinicalTrials.gov
• 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients#981629ClinicalTrials.gov
• Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France#994070ClinicalTrials.gov
• Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer#918714ClinicalTrials.gov
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors#810907ClinicalTrials.gov
• A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors#827224ClinicalTrials.gov
• Polonez 1908 : pamięci Andrzeja hr. Potockiego#301357Kujawsko-Pomorska Biblioteka Cyfrowa
• Multi expert integrated algorithm for kidney biopsy triage.#301604NCBI PubMed Central
• Closed-Loop Optogenetic Control in a Microplate Reader.#309029NCBI PubMed Central
• HR adviseur - Cluster BCO#347477EU Publications
• HR adviseur - Cluster BCO#347478EU Publications
• HR adviseur - Cluster BCO#347479EU Publications
• P2 HF-HRV, high freq HR variability, 0.15-0.50 Hz#407534AutoGenerated_1331
• S2 HF-HRV, high freq HR variability, 0.15-0.50 Hz#407536AutoGenerated_1331